840 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by Grant Private Wealth Management Inc

Grant Private Wealth Management Inc acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 840 shares of the company’s stock, valued at approximately $279,000.

Several other large investors also recently modified their holdings of the stock. Bank of Montreal Can boosted its stake in Medpace by 42.6% in the 3rd quarter. Bank of Montreal Can now owns 5,874 shares of the company’s stock valued at $1,947,000 after buying an additional 1,755 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Medpace by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 21,469 shares of the company’s stock valued at $7,166,000 after purchasing an additional 340 shares in the last quarter. FMR LLC grew its holdings in shares of Medpace by 11.8% in the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after purchasing an additional 24,362 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Medpace by 8.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,122 shares of the company’s stock worth $2,377,000 after purchasing an additional 545 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in Medpace during the 3rd quarter valued at about $479,000. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent analyst reports. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Stock Up 4.5 %

Medpace stock opened at $311.23 on Thursday. The business’s 50-day simple moving average is $333.58 and its 200 day simple moving average is $338.33. The stock has a market cap of $9.48 billion, a price-to-earnings ratio of 24.64, a P/E/G ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a 12-month low of $289.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.